



International Meeting on

Pharmacovigilance in Psychiatry Therapeutic Drug Monitoring and Pharmacogenetics of Psychotropic Drugs

Lausanne | Switzerland
1-3 september '04

A joint meeting of the

AGNP-TDM group
of the Arbeitsgemeinschaft für Neuropsychopharmakologie
und Pharmakopsychiatrie (AGNP)
(Association of Neuropsychopharmacology and
Pharmacopsychiatry)

and the

SGAMSP
Schweizerische Gesellschaft
für Arzneimittelicherheit in der Psychiatrie
Société suisse de pharmacovigilance en psychiatrie
(Swiss Society of Pharmacovigilance in Psychiatry)

in collaboration with the

AGNP
AMSP e. V. - Germany
ÖAMSP (Austrian Society of Pharmacovigilance in Psychiatry)

Conference secretary

Viveka Sari
Unité de biochimie et psychopharmacologie clinique
Univ Dept Adult Psychiatrie
Center of Psychiatric Neurosciences
Site de Cery
CH-1008 Prilly-Lausanne/Switzerland

E-mail: viveka.sari@inst.hospvd.ch
Tel + 41 21 643 643 2
Fax + 41 21 643 64 44

Info:

Prof Dr Pierre Baumann
UBPC, DUPA and CNP
CH-1008 Prilly-Lausanne/Switzerland

pierre.baumann@inst.hospvd.ch
tel. +41 21 643 643 4
fax +41 21 643 64 44

www.agnp.de
www.hospvd.ch/psy/cnp

Stamp please

Mrs Viveka Sari
Unité de biochimie et psychopharmacologie clinique
Département universitaire de psychiatrie adulte
Centre de Neurosciences psychiatriques
CH-1008 Prilly-Lausanne
Switzerland




Photo: B. Colombo - Lausanne Tourisme | Grafische: CEMAV-CHN

International Meeting on

Pharmacovigilance in Psychiatry Therapeutic Drug Monitoring and Pharmacogenetics of Psychotropic Drugs

1st Announcement

**UNIVERSITÄT
DE LAUSANNE**
University of Lausanne
Department of Psychiatry
(DP-CHUV)

Lausanne | Switzerland

1-3
September '04



Pharmacovigilance in Psychiatry

Therapeutic Drug Monitoring and Pharmacogenetics of Psychotropic Drugs

Welcome

Organising committee:

Pierre Baumann (chair), Lausanne, Switzerland (SGAMSP; AGNP- TDM group)
 Eveline Jaquenoud Siroz, Königsfelden-Bugg, Switzerland (SGAMSP)
 Siegfried Kasper, Vienna, Austria (ÖAMSP)
 Rolf Engel, Munich, Germany (AMSP e.V.)
 Bruno Müller-Oerlinghausen, Berlin (AGNP-TDM group)
 Walter E. Müller, Frankfurt, Germany (AGNP)

Advisory board

Finn Bengtsson, Linköping, Sweden
 Jérôme Biollaz, Lausanne, Switzerland
 Thierry Buclin, Lausanne, Switzerland
 Chin B. Eap, Lausanne, Switzerland
 Pascale Jolliet, Nantes, France
 Renate Grohmann, Munich, Germany
 Hanns Hippus, Munich, Germany
 Eckart Rütther, Goettingen, Germany
 Jan Willem van der Velden, Zumikon, Switzerland

Members of the AGNP- TDM group

Pierre Baumann, Lausanne, Switzerland (president)
 Gabriel Eckermann, Kaufbeuren, Germany
 Ines Gaertner, Tübingen, Germany
 Manfred Gerlach, Würzburg, Germany
 Christoph Hiemke, Mainz, Germany
 Hans-Joachim Kuss, Munich, Germany
 Gerd Laux, Wasserburg, Germany
 Bruno Müller-Oerlinghausen, Berlin, Germany
 Marie Luise Rao, Bonn, Germany
 Peter Riederer, Würzburg, Germany
 Sven Ulrich, Magdeburg, Germany
 Gerald Zernig, Innsbruck, Austria

Members of the SGAMSP Committee (Switzerland)

Pierre Baumann, Lausanne (president)
 Eveline Jaquenoud Siroz, Königsfelden-Bugg (vice-president)
 Andreas Horvath, Kilchberg (secretary)
 Waldemar Grell, Kilchberg (cashier)
 Kätrin Angst, Zurich (member)
 Daniele Zullino, Lausanne (member)
 Karin Verbot-Gaud, Geneva (member)
 Ernst Kradoffer, Zug (member)

Dear colleague,

We are pleased to invite you to this scientific meeting, which will be centered on therapeutic drug monitoring (TDM) and pharmacogenetics of psychotropic drugs (September 1 and 2) and to pharmacovigilance in psychiatry (September 2 and 3). Many common sessions of September 2 will be devoted to pharmacokinetic and pharmacogenetic aspects in pharmacovigilance in psychiatry.

Therefore, this congress will be of interest for psychiatrists, clinical psychopharmacologists, clinical pharmacists, psychologists, analytical chemists, clinical biochemists personnel working in pharmacovigilance and laboratory practitioners.

Pharmacovigilance in psychiatry has gained much importance since in many countries the reporting and assessment of adverse drug reactions (ADR) to a governmental organization is now mandatory. In some countries, societies were created in the aim to examine on a scientific basis the epidemiology and causes of ADRs. Such pharmacovigilance projects (AMSP projects) were eventually introduced in Austria, Germany and Switzerland.

Both pharmacokinetic and pharmacodynamic factors codetermine the clinical effectiveness of psychotropic drugs. Therapeutic drug monitoring and pharmacogenetic tests allow examining the influence of the environment and of the genetic constitution of the patient on the fate of the drug in the organism.

These methods are not only useful for research but also for clinical purposes, in situations where medication needs to be adapted in order to obtain an optimal clinical effectiveness and to avoid ADRs. They also help to determine the contribution of pharmacokinetic and pharmacogenetic factors in the apparition of ADRs. Pharmacogenetic factors comprise both those related to drug metabolism (cytochrome P-450) and drug transport, as well as those related to their dynamics (receptor polymorphisms, etc).

There will be symposia, workshops and poster sessions at this meeting, and you are encouraged to submit proposals. There will be an exhibition by companies working in the field of psychopharmacology or in drug analysis, and by equipment and reactant providers.

Venue of the congress is the university campus at the Lake of Geneva shore, only 10 – 15 minutes away from the center of Lausanne by public transportation. The airport of Geneva may be reached within 45 min, either by car or by train.

Prof. Dr. Pierre Baumann

Request for further information

Last name: _____

Address: _____

Post code: _____

City: _____

Country: _____

Fax: _____

Tel: _____

I wish to present: a poster

an oral communication

Comments and questions: